Harbin Medisan Pharmaceutical Co., Ltd.
Symbol: 002900.SZ
SHZ
10.31
CNYMarkedspris i dag
62.4601
P/E-forhold
1.8348
PEG Ratio
3.19B
MRK Cap
- 0.01%
DIV Udbytte
Harbin Medisan Pharmaceutical Co., Ltd. (002900-SZ) Årsregnskaber
Balance
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 1048.9 | 1293.9 | 1111.5 | ||||||||||||
balance-sheet.row.short-term-investments | 0 | 57.8 | 91.3 | 581.7 | ||||||||||||
balance-sheet.row.net-receivables | 0 | 150.6 | 164.1 | 149.6 | ||||||||||||
balance-sheet.row.inventory | 0 | 208.8 | 161.2 | 156.5 | ||||||||||||
balance-sheet.row.other-current-assets | 0 | 28.2 | 4.5 | 9.5 | ||||||||||||
balance-sheet.row.total-current-assets | 0 | 1436.4 | 1623.7 | 1427.2 | ||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 1081.6 | 882.4 | 925.3 | ||||||||||||
balance-sheet.row.goodwill | 0 | 1.3 | 0.5 | 9.4 | ||||||||||||
balance-sheet.row.intangible-assets | 0 | 141.2 | 71.7 | 62.5 | ||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 142.5 | 72.2 | 71.9 | ||||||||||||
balance-sheet.row.long-term-investments | 0 | 651.2 | 555.6 | 22.8 | ||||||||||||
balance-sheet.row.tax-assets | 0 | 23.1 | 23.8 | 25.8 | ||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 108.1 | 119.1 | 592.4 | ||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 2006.5 | 1653.1 | 1638.3 | ||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-assets | 0 | 3443 | 3276.8 | 3065.5 | ||||||||||||
balance-sheet.row.account-payables | 0 | 182.1 | 120.8 | 105.2 | ||||||||||||
balance-sheet.row.short-term-debt | 0 | 480.2 | 233.8 | 274.8 | ||||||||||||
balance-sheet.row.tax-payables | 0 | 3.1 | 12.2 | 11.2 | ||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 238.2 | 422.9 | 212.9 | ||||||||||||
Deferred Revenue Non Current | 0 | 79 | 83.9 | 89 | ||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||
balance-sheet.row.other-current-liab | 0 | 7.9 | 188.3 | 2.5 | ||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 449.7 | 627.1 | 412.4 | ||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 8.3 | 5.1 | 8 | ||||||||||||
balance-sheet.row.total-liab | 0 | 1294.8 | 1224.8 | 949 | ||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.common-stock | 0 | 316.4 | 316.6 | 316.6 | ||||||||||||
balance-sheet.row.retained-earnings | 0 | 612.9 | 570.7 | 639.6 | ||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 162.5 | 192.3 | ||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 1211.2 | 990.9 | 952.9 | ||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 2140.5 | 2040.7 | 2101.4 | ||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 3443 | 3276.8 | 3065.5 | ||||||||||||
balance-sheet.row.minority-interest | 0 | 7.7 | 11.3 | 15 | ||||||||||||
balance-sheet.row.total-equity | 0 | 2148.2 | 2052 | 2116.5 | ||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||||
Total Investments | 0 | 709 | 646.9 | 604.5 | ||||||||||||
balance-sheet.row.total-debt | 0 | 718.4 | 656.7 | 487.7 | ||||||||||||
balance-sheet.row.net-debt | 0 | -272.8 | -545.9 | -42.2 |
Pengestrømsopgørelse
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 26.5 | 349.7 | 26.6 | |||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 106.6 | 99.1 | 79.9 | |||||||||||
cash-flows.row.deferred-income-tax | 0 | 11.7 | 95 | -1.4 | |||||||||||
cash-flows.row.stock-based-compensation | 0 | -11.7 | -95 | 1.4 | |||||||||||
cash-flows.row.change-in-working-capital | 0 | 49.5 | 107.4 | -160.1 | |||||||||||
cash-flows.row.account-receivables | 0 | -10 | 49.6 | 49.1 | |||||||||||
cash-flows.row.inventory | 0 | 0.6 | 26.5 | 31.9 | |||||||||||
cash-flows.row.account-payables | 0 | 47.2 | -63.7 | -239.6 | |||||||||||
cash-flows.row.other-working-capital | 0 | 11.7 | 95 | -1.4 | |||||||||||
cash-flows.row.other-non-cash-items | 0 | -37.9 | -568.8 | 49 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -89.2 | -73.9 | -145.9 | |||||||||||
cash-flows.row.acquisitions-net | 0 | 0.3 | 11.6 | 146.4 | |||||||||||
cash-flows.row.purchases-of-investments | 0 | -72 | -1113.7 | -1091 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 580.2 | 901.9 | 1437.6 | |||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | -4.1 | -145.9 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 419.3 | -278.2 | 201.3 | |||||||||||
cash-flows.row.debt-repayment | 0 | -270.2 | -269.5 | -230 | |||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.dividends-paid | 0 | -109.3 | -34.3 | -95.8 | |||||||||||
cash-flows.row.other-financing-activites | 0 | 272.4 | 260.1 | 323.2 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -107.1 | -43.7 | -2.6 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.net-change-in-cash | 0 | 456.8 | -334.5 | 194.2 | |||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 782.3 | 325.5 | 660 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 325.5 | 660 | 465.7 | |||||||||||
cash-flows.row.operating-cash-flow | 0 | 144.6 | -12.5 | -4.5 | |||||||||||
cash-flows.row.capital-expenditure | 0 | -89.2 | -73.9 | -145.9 | |||||||||||
cash-flows.row.free-cash-flow | 0 | 55.4 | -86.5 | -150.4 |
Resultatopgørelse række
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 1186.8 | 1028.4 | 945.8 | ||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 476.4 | 365.6 | 309.4 | ||||||||||||
income-statement-row.row.gross-profit | 0 | 710.4 | 662.8 | 636.4 | ||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-expenses | 0 | 2.4 | 110.5 | 46.5 | ||||||||||||
income-statement-row.row.operating-expenses | 0 | 693.4 | 679.6 | 765.2 | ||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 1169.7 | 1045.1 | 1074.6 | ||||||||||||
income-statement-row.row.interest-income | 0 | 27.9 | 28.3 | 11.8 | ||||||||||||
income-statement-row.row.interest-expense | 0 | 22.9 | 22.6 | 13.8 | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 2.4 | -17.5 | -1.9 | ||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 2.4 | 110.5 | 46.5 | ||||||||||||
income-statement-row.row.total-operating-expenses | 0 | 2.4 | -17.5 | -1.9 | ||||||||||||
income-statement-row.row.interest-expense | 0 | 22.9 | 22.6 | 13.8 | ||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 108.7 | 106.6 | 122.9 | ||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||||
income-statement-row.row.operating-income | 0 | 79 | 57.6 | 454.8 | ||||||||||||
income-statement-row.row.income-before-tax | 0 | 81.4 | 40.1 | 452.9 | ||||||||||||
income-statement-row.row.income-tax-expense | 0 | 11.3 | 13.6 | 103.2 | ||||||||||||
income-statement-row.row.net-income | 0 | 73.7 | 30.2 | 351 |
Ofte stillede spørgsmål
Hvad er Harbin Medisan Pharmaceutical Co., Ltd. (002900.SZ) samlede aktiver?
Harbin Medisan Pharmaceutical Co., Ltd. (002900.SZ) samlede aktiver er 3442984089.000.
Hvad er virksomhedens årlige omsætning?
Den årlige omsætning er N/A.
Hvad er virksomhedens profitmargin?
Virksomhedens profitmargin er 0.582.
Hvad er virksomhedens frie pengestrøm?
Det frie cash flow er -1.022.
Hvad er virksomhedens nettoprofitmargin?
Nettofortjenstmargenen er 0.049.
Hvad er firmaets samlede omsætning?
Den samlede omsætning er 0.026.
Hvad er Harbin Medisan Pharmaceutical Co., Ltd. (002900.SZ) nettoresultat (nettoindkomst)?
Nettoresultatet (nettoindkomsten) er 73663110.000.
Hvad er virksomhedens samlede gæld?
Den samlede gæld er 718376453.000.
Hvad er tallet for driftsudgifter?
Driftsudgifterne er 693357200.000.
Hvad er firmaets likviditet?
Virksomhedens likviditet er 0.000.